Search results
Results from the WOW.Com Content Network
Allopurinol is used to reduce urate formation in conditions where urate deposition has already occurred or is predictable. The specific diseases and conditions where it is used include gouty arthritis, skin tophi, kidney stones, idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate ...
Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval. The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents.
Allopurinol hypersensitivity syndrome (AHS) typically occurs in persons with preexisting kidney failure. [3]: 119 Weeks to months after allopurinol is begun, the patient develops a morbilliform eruption [3]: 119 or, less commonly, develops one of the far more serious and potentially lethal severe cutaneous adverse reactions viz., the DRESS syndrome, Stevens Johnson syndrome, or toxic epidermal ...
The FDA first warned in September that the drug could cause liver problems. It escalated that warning after reviewing the case of a person with blood markers of liver injury who had been taking ...
A hepatotoxin (Gr., hepato = liver) is a toxic chemical substance that damages the liver.. It can be a side-effect, but hepatotoxins are also found naturally, such as microcystins and pyrrolizidine alkaloids, or in laboratory environments, such as carbon tetrachloride, or far more pervasively in the form of ethanol (drinking alcohol).
Dr. Clarke notes that mild liver damage usually starts with loss of appetite and fatigue, while more acute or severe liver damage has other symptoms. If you ever notice that you have jaundice, see ...
For premium support please call: 800-290-4726 more ways to reach us
The FDA required Takeda to conduct this safety study when the medicine was approved in 2009. The febuxostat drug labels already carry a warning and precaution about cardiovascular events because the clinical trials conducted before approval showed a higher rate of heart-related problems in patients treated with febuxostat compared to allopurinol.